Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461338 | 0.77 | CA12 (0.40) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL8683462 | 0.75 | CA12 (0.39) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL5455141 | 0.75 | CA12 (0.39) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL5452741 | 0.75 | CA12 (0.36) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL400031 | 0.73 | ATM (0.40) | KDM4EALDH1A1HBBHSD17B10ATM | |
| SCHEMBL11836412 | 0.68 | PRDX1 (0.35) | KDM4EALDH1A1HBBHSD17B10SMN1; SMN2 | |
| SCHEMBL13084389 | 0.66 | ATM (0.37) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL6365684 | 0.66 | ATM (0.37) | CA12CA1CA2CA9KDM4E | |
| Tirapazamine SCHEMBL29360622 | 0.66 | CA12 (0.39) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL15008539 | 0.66 | ATM (0.37) | CA12CA1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254122-B1 | NOVEL 3-SUBSTITUTED 1,2,4-BENZOTRIAZINES, A METHOD FOR THEIR PRODUCTION AND THE USE THEREOF | UFZ LEIPZIGHALLE GMBH (DE) | 2008-09-17 | — | — | EP | disclosed |
| US-20030166651-A1 | Novel 3-substituted 1,2,4-benzotriazines, a method for their production and the use thereof | UFZ UMWELTFORSCHUNGSZENTRUM LEIPZIG-HALLE GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1254122-A2 | NOVEL 3-SUBSTITUTED 1,2,4-BENZOTRIAZINES, A METHOD FOR THEIR PRODUCTION AND THE USE THEREOF | UFZ-UMWELTFORSCHUNGSZENTRUM Leipzig-Halle GmbH (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001046162-A2 | NOVEL 3-SUBSTITUTED 1,2,4-BENZOTRIAZINES, A METHOD FOR THEIR PRODUCTION AND THE USE THEREOF FOR THE TREATMENT AND PROPHYLAXIS OF TUMOURS | UFZ UMWELTFORSCHUNGSZENTRUM LEIPZIG-HALLE GMBH (DE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166651-A1 | Novel 3-substituted 1,2,4-benzotriazines, a method for their production and the use thereof | RYR2, CACNA1I, BRCA1 | CA12 2158/4885CA1 1239/4885CA2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.